Overcoming Complications in Cross-Border Licensing Deals with China

10:45 AM - 12:00 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 6B

Partnering activity in China continued to accelerate in 2021 with 658 deals generating a record $42 billion in deal value, and over 50% of the cross border deals being done with U.S. companies and 25% with EU companies. However, the pandemic and geopolitical tensions have complicated negotiating and closing deals recently.  The panel will discuss successful practices for identifying and pursuing cross-border licensing deals in the current climate so new medicines will be able to reach patients both inside China and around the world faster.

Moderator
photo
CBO
Scenic Biotech
Speakers
photo
Global Head Asia Partnering
Roche
photo
Chief Financial Officer
Elpiscience Biopharmaceuticals
photo
CEO
Exuma Biotech Corp.
photo
CBO
LianBio
photo
CBO
I-Mab Biopharma US Limited